LTRN
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Lantern Pharma Inc. (LTRN) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F). The rating has held at D+ for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B+ (3.7) | D (1.3) | F (0.5) | F (0.4) | C+ (2.6) | D+ (1.7) |
| 2026-11-06 | A- (3.9) | D (1.3) | F (0.5) | F (0.6) | C+ (2.7) | D+ (1.8) |
| 2026-10-30 | C+ (2.5) | D (1.3) | F (0.6) | F (0.7) | C+ (2.7) | D+ (1.5) |
| 2026-10-23 | C+ (2.5) | D (1.3) | F (0.6) | D- (0.8) | C+ (2.6) | D+ (1.5) |
| 2026-10-16 | C+ (2.5) | D (1.3) | F (0.6) | D- (1.0) | C+ (2.6) | D+ (1.6) |